Helius Medical Technologies (Nasdaq:HSDT) announced today that it established Revelation Neuro, a brain-computer interface (BCI) subsidiary. The wholly-owned private subsidiary focuses on the development of non-implantable, AI-powered BCI technology. It aims to produce a unique, less invasive option. “We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of […]
Helius Medical Technologies
Neurostim tech developer Helius Medical prices $18M offering
Helius Medical Technologies (Nasdaq:HSDT) announced today that it priced a public offering of common stock worth $18 million. Newtown, Pennsylvania-based Helius, which develops the PoNS (portable neuromodulation stimulator), is offering 24 million shares of Class A common stock and warrants to purchase up to 36 million shares of Class A common stock at a purchase […]
Helius Medical wins FDA nod for tongue stimulator that improves MS patients’ gait
The FDA announced today that it authorized marketing for a stimulator device that treats gait deficit in those with multiple sclerosis (MS). Helius Medical’s portable neuromodulation stimulator (PoNS) is a neuromuscular tongue stimulator that uses a non-implantable apparatus to generate electrical pulses for stimulation of the trigeminal and facial nerves via the tongue to treat […]
Helius Medical shares tank on FDA denial
Shares in Helius Medical Technologies (NSDQ:HSDT) tanked yesterday after the company said the FDA shot down its clearance bid for the portable neuromodulation device it developed. The Newtown, Pa.-based company’s PONS system is designed to treat neurological symptoms through electrical stimulation of nerves in the tongue. A trial of the PONS device in treating patients with […]
Natus Medical lifts Kennedy to the corner office | Personnel Moves – July 17, 2018
Natus Medical (Nasdaq: BABY) said last week that its current CEO Jim Hawkins is retiring from their position, with current chief financial officer Jonathan Kennedy slated to take over as prez & chief exec. Kennedy has operated as CFO since April 2013, while the retiring Hawkins spent 14 years as the chief exec, the Pleasanton, Calif.-based company said. […]
Helius Medical touts PoNS TBI-treatment trial data despite primary effectiveness miss
Helius Medical Technologies (TSX:HSM) today released results from a registrational trial of its Portable Neuromodulation Stimulator, used to treat patients with chronic balance deficits due to mild-to-moderate traumatic brain injuries, touting positive effects but a missed primary effectiveness endpoint. The Newtown, Penn.-based company’s PONS system is designed to treat neurological symptoms, caused by trauma or disease, non-invasively […]
Helius inks 5-year lease for new Pennsylvania headquarters
Helius Medical Technologies (TSX:HSM) said today it inked a 5-year lease on a piece of property that will serve as its corporate headquarters. The property, 10,400 square feet of space at Newtown Commons West outside Philadelphia, will serve as corporate headquarters, a clinical research site and a physical therapy training center. The company plans to move in July […]
Helius Medical closes $10m offering for portable neurostim trials
Helius Medical Technologies (TSX:HSM) said today that it closed an offering worth nearly $10 million (C$12.5 million) for the portable neurostimulation device it’s developing. Newtown, Pa.-based Helius said it plans to use the proceeds from the 6.6-million-share flotation to complete a trial of the PoNS therapy in treating mild to moderate brain injury and the launch […]
Helius Medical touts data from multiple sclerosis pilot study of PONS system
Helius Medical Technologies said today that clinical data from a multiple sclerosis pilot study of its portable neuromodulation stimulator was published in the Multiple Sclerosis Journal: Experimental, Translational and Clinical. The company’s PONS system is designed to treat neurological symptoms, caused by trauma or disease, non-invasively through the tongue. Helius’ pilot study evaluated its PONS device combined […]
Helius Medical extends U.S. Army contract, looks to future of portable neuromod
Helius Medical Technologies said this week it expanded a source cost sharing contract with the U.S. Army Medical Research and Materiel Command, while its CEO Phil Deschamps is looking to the future of its Portable Neuromodulation Stimulator. The contract extension moves the ending date to December 31, 2017 and allows for additional study sites in a trial […]
Helius touts 6-patient study of advanced MS cases
Helius Medical Technologies this week released the result of a 6-patient pilot study of its PoNS therapy used to treat the advanced symptoms of multiple sclerosis, touting improvements in physical, cognitive and quality of life parameters. Data from the study was presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers this […]
